SCHEMBL6520060

SCHEMBL6520060

CC(C)c1c[nH]c2ccc(Oc3c(Cl)cc(NCC(=O)C(=O)O)cc3Cl)cc12

nearest known ligand 0.67

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
THRB P10828 14/20 0.67
THRA P10827 13/20 0.67
RORC P51449 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6512564 0.94 THRA (0.68) THRBTHRA
SCHEMBL6520528 0.94 THRA (0.59) THRBTHRA
SCHEMBL6518476 0.92 THRA (0.69) THRBTHRA
SCHEMBL6511534 0.91 THRA (0.61) THRBTHRA
SCHEMBL6515753 0.89 THRA (0.66) THRBTHRA
SCHEMBL6515542 0.88 THRA (0.65) THRBTHRA
SCHEMBL6512125 0.87 THRA (0.70) THRBTHRA
SCHEMBL6515955 0.87 THRA (0.72) THRBTHRA
SCHEMBL6512501 0.86 THRA (0.69) THRBTHRA
SCHEMBL6512776 0.86 THRA (0.61) THRBTHRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032874-A1 Anticholesterol agents; arteriosclerosis BAYER AKTIENGESELLSCHAFT (DE) 2005-02-10 US disclosed
US-6794406-B2 FOR THERAPY AND PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA BAYER AKTIENGESELLSCHAFT (DE) 2004-09-21 US disclosed
US-20030078288-A1 Indole derivatives BAYER AKTIENGESELLSCHAFT (DE) 2003-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078288-A1 Indole derivatives IDO1, IDO2, TPH2 THRB 1772/4885THRA 2460/4885RORC 468/4885
US-20050032874-A1 Anticholesterol agents; arteriosclerosis HMGCR, CYP46A1, EBP THRB 1835/4885THRA 1917/4885RORC 544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.